INFLUENCE OF RIMONABENT ON ORAL HYPOGLYCAEMIC ACTIVITY OF GLIBENCLAMIDE: A PHARMACOKINETIC DRUG- DRUG INTERACTION STUDY

This study investigates the pharmacokinetic interaction between rimonabant, a cannabinoid receptor 1 (CB1) antagonist, and glibenclamide, a sulfonylurea used for its hypoglycemic effects, in albino rats. Given the frequent co-occurrence of obesity and type II diabetes, understanding interactions between anti-obesity and antidiabetic medications is crucial for optimizing therapeutic regimens. Blood was collected at pre-determined hiatus to measure glucose echelon using GOD/POD method, with serum separated by centrifugation and analyzed. Our findings reveal that rimonabant alters hypoglycemic effect of glibenclamide. This interaction suggests that rimonabant may improve insulin sensitivity and beta-cell function, augmenting glibenclamide’s glucose-lowering effect. These results highlight the potential for combined therapy in managing diabetes and obesity, offering insights into dose optimization to minimize side effects such as hypoglycemia.